| Views | |
|---|---|
| Multicenter Phase I Study of Erdafitinib (JNJ-42756493) Oral Pan-Fibroblast Growth Factor Receptor Inhibitor in Patients with Advanced or Refractory Solid Tumors | 73 |
| January 2024 | February 2024 | March 2024 | April 2024 | May 2024 | June 2024 | July 2024 | |
|---|---|---|---|---|---|---|---|
| Multicenter Phase I Study of Erdafitinib (JNJ-42756493) Oral Pan-Fibroblast Growth Factor Receptor Inhibitor in Patients with Advanced or Refractory Solid Tumors | 9 | 30 | 3 | 7 | 4 | 11 | 9 |
| Views | |
|---|---|
| artconlli_a2019_tabernero_josep_multicenter_phase I_study.pdf | 56 |
| Views | |
|---|---|
| United States | 32 |
| China | 8 |
| South Korea | 2 |
| Colombia | 1 |
| Spain | 1 |
| Views | |
|---|---|
| Menlo Park | 10 |
| Shanghai | 6 |
| Oakland | 5 |
| San Diego | 4 |
| Ann Arbor | 3 |
| Houston | 2 |
| Atlanta | 1 |
| Barcelona | 1 |
| Boardman | 1 |
| Guangzhou | 1 |